Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF‐κB subunit RelA.
| Autor: | van Dijk, Anneke D., Hoff, Fieke W., Qiu, Yihua, Gerbing, Robert B., Gamis, Alan S., Aplenc, Richard, Kolb, E. Anders, Alonzo, Todd A., Meshinchi, Soheil, Jenkins, Gaye N., de Bont, Eveline S. J. M., Kornblau, Steven M., Horton, Terzah M. |
|---|---|
| Zdroj: | Proteomics - Clinical Applications; Mar2022, Vol. 16 Issue 2, p1-11, 11p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|
Plný text